{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:06:08Z","timestamp":1789790768418,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jdiacomp.2025.109147","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T15:08:21Z","timestamp":1754492901000},"page":"109147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The prevalence and correlates of advanced fibrosis in patients with and without diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A cross-sectional study"],"prefix":"10.1016","volume":"39","author":[{"given":"Emir","family":"Muzurovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Topi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevena","family":"Todorovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Ze\u010devi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2025.109147_bb0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154770","article-title":"Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk","volume":"119","author":"Muzurovi\u0107","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0015","doi-asserted-by":"crossref","DOI":"10.1177\/10742484221146371","volume":"27","author":"Muzurovi\u0107","year":"2022","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0020","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000251","article-title":"The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019","volume":"7","author":"Paik","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0025","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0030","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/HYPERTENSIONAHA.122.17982","article-title":"Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors","volume":"79","author":"Muzurovi\u0107","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/0115701611340703240809044916","article-title":"Metabolic dysfunction-associated steatohepatitis and cardiovascular disease prevention - is Resmetirom useful?","volume":"23","author":"Borozan","year":"2025","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0040","article-title":"Liver fibrosis and atherosclerosis, a consequence of metabolic dysfunction-do they share a similar pathophysiological background?","author":"Muzurovi\u0107","year":"2024","journal-title":"Angiology"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2024.108875","article-title":"Monitoring the liver as a part of the cardio-renal-metabolic continuum - what is cooking and burning with non-invasive tests and treatment options?","volume":"38","author":"Vol\u010dan\u0161ek","year":"2024","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0050","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"NAFLD nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0055","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/pharmrev.123.001087","article-title":"Steatotic liver disease: pathophysiology and emerging pharmacotherapies","volume":"76","author":"Kokkorakis","year":"2024","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2024.108910","article-title":"Predictors of liver fibrosis progression in cohort of type 2 diabetes mellitus patients with MASLD","volume":"39","author":"Alfadda","year":"2025","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0065","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cgh.2023.09.018","article-title":"Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of 129 studies","volume":"22","author":"Chan","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0070","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0075","doi-asserted-by":"crossref","first-page":"12489","DOI":"10.3390\/ijms232012489","article-title":"Accuracy of FIB-4 to detect elevated liver stiffness measurements in patients with non-alcoholic fatty liver disease: a cross-sectional study in referral centers","volume":"23","author":"Vigan\u00f2","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0080","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.2337\/dc25-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0085","first-page":"661","article-title":"Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD","volume":"8","author":"Alkhouri","year":"2012","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0090","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.2337\/dc25-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/life11020143","article-title":"FIB-4 first in the diagnostic algorithm of metabolic-dysfunction-associated fatty liver disease in the era of the global metabodemic","volume":"11","author":"Sumida","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jmu.2017.04.001","article-title":"Ultrasound evaluation of liver fibrosis","volume":"25","author":"Lin","year":"2017","journal-title":"J Med Ultrasound"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0105","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0110","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","author":"Younossi","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0115","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0120","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2337\/dc22-2048","article-title":"QUID-NASH investigators. High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold","volume":"46","author":"Castera","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40001-015-0090-z","article-title":"Role of receptor for advanced glycation end products (RAGE) in liver disease","volume":"20","author":"Yamagishi","year":"2015","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0130","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/nu11040872","article-title":"Oxidative stress and non-alcoholic fatty liver disease: effects of omega-3 fatty acid supplementation","volume":"11","author":"Yang","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166148","article-title":"Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus","volume":"1867","author":"Giglio","year":"2021","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000282083","article-title":"The role of cytokines in non-alcoholic fatty liver disease","volume":"28","author":"Tilg","year":"2010","journal-title":"Dig Dis"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0145","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jhep.2018.06.008","article-title":"Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease","volume":"69","author":"Lebeaupin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0150","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/antiox12061172","article-title":"From obesity-induced low-grade inflammation to lipotoxicity and mitochondrial dysfunction: altered multi-crosstalk between adipose tissue and metabolically active organs","volume":"12","author":"Cavaliere","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0155","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.metabol.2015.11.006","article-title":"Adipokines in nonalcoholic fatty liver disease","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0160","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/157016112001211228145754","article-title":"Epicardial adipocyte-derived TNF-\u03b1 modulates local inflammation in patients with advanced coronary artery disease","volume":"20","author":"Muzurovi\u0107","year":"2022","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0165","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000527595","article-title":"Obesity-induced hepatic steatosis is partly mediated by visceral fat accumulation in subjects with overweight\/obesity: a cross-sectional study","volume":"16","author":"Liu","year":"2023","journal-title":"Obes Facts"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0170","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s13300-024-01615-5","article-title":"Modern management of cardiometabolic continuum: from overweight\/obesity to prediabetes\/type 2 diabetes mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group","volume":"15","author":"Janez","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0175","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jdiacomp.2025.109147_bb0180","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2337\/dc24-2075","article-title":"Screening for metabolic dysfunction-associated steatotic liver disease-related advanced fibrosis in diabetology: a prospective multicenter study","volume":"48","author":"Caussy","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0185","doi-asserted-by":"crossref","DOI":"10.3138\/canlivj-2024-0063","article-title":"Validation of FIB-4 for the diagnosis of liver cirrhosis in metabolic dysfunction-associated steatotic liver disease","author":"Bera","year":"2025","journal-title":"Can Liver J"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0190","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.jhep.2022.06.016","article-title":"Low accuracy of FIB-4 test to identify people with diabetes at low risk of advanced fibrosis","volume":"77","author":"Gracen","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0195","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","article-title":"Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events","volume":"76","author":"Boursier","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0200","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1210\/jc.2015-3444","article-title":"Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies","volume":"101","author":"Loomis","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155937","article-title":"Obesity and MASLD: is weight loss the (only) key to treat metabolic liver disease?","volume":"157","author":"Huttasch","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0210","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.3390\/nu16111586","article-title":"The link between abdominal obesity indices and the progression of liver fibrosis: insights from a population-based study","volume":"16","author":"Juli\u00e1n","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0215","doi-asserted-by":"crossref","first-page":"28951","DOI":"10.1038\/s41598-024-79428-6","article-title":"Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms","volume":"14","author":"Lee","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0220","doi-asserted-by":"crossref","first-page":"1083032","DOI":"10.3389\/fendo.2023.1083032","article-title":"Prediction of MAFLD and NAFLD using different screening indexes: a cross-sectional study in U.S. adults","volume":"14","author":"Peng","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0225","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13098-024-01571-x","article-title":"Prediction of MASLD using different screening indexes in Chinese type 2 diabetes mellitus","volume":"17","author":"Hu","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0230","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12876-021-01974-4","article-title":"The liver steatosis severity and lipid characteristics in primary biliary cholangitis","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0235","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/0004563219853596","article-title":"The association between lecithin-cholesterol acyltransferase activity and fatty liver index","volume":"56","author":"Janac","year":"2019","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0240","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3390\/cells8101259","article-title":"Potential therapeutic application of estrogen in gender disparity of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"8","author":"Lee","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0245","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1016\/j.jhep.2023.08.013","article-title":"Heart-liver axis research collaboration. Sex differences in prevalence and prognosis of steatotic liver disease phenotypes: biological sex matters","volume":"80","author":"Ji","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2025.109147_bb0250","doi-asserted-by":"crossref","first-page":"F1117","DOI":"10.1152\/ajprenal.00320.2020","article-title":"Sex differences in renal mitochondrial function: a hormone-gous opportunity for research","volume":"319","author":"Sultanova","year":"2020","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725002004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725002004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:31:54Z","timestamp":1757197914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872725002004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1056872725002004"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109147","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prevalence and correlates of advanced fibrosis in patients with and without diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109147"}}